APT vs SRPT vs BMRN vs LAKE

For growth investors, Lakeland Industries, Inc.

(LAKE) is the stronger pick with 34. 1% revenue growth year-over-year, versus 2. 3% for Alpha Pro Tech, Ltd. (APT). Alpha Pro Tech, Ltd. (APT) offers the better valuation at 19. 5x trailing P/E, making it the more compelling value choice. Analysts rate Sarepta Therapeutics, Inc. (SRPT) a "Buy" — based on 54 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alpha Pro Tech, Ltd.

(APT) is the cheapest at 19. 5x versus BioMarin Pharmaceutical Inc. at 30. 0x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alpha Pro Tech, Ltd.

(APT) delivered a total return of -25. 5%, compared to -71. 5% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: APT returned +209. 1% versus BMRN's -35. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alpha Pro Tech, Ltd.

(APT) is the lower-risk stock at 0. 39β versus Sarepta Therapeutics, Inc. 's 1. 95β — meaning SRPT is approximately 396% more volatile than APT relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lakeland Industries, Inc.

(LAKE) is pulling ahead at 34. 1% versus 2. 3% for Alpha Pro Tech, Ltd. (APT). On earnings-per-share growth, the picture is similar: Alpha Pro Tech, Ltd. grew EPS -5. 7% year-over-year, compared to -437. 5% for Lakeland Industries, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioMarin Pharmaceutical Inc.

(BMRN) is the more profitable company, earning 10. 8% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — BMRN leads at 77. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 5. 9x forward P/E versus 13. 6x for BioMarin Pharmaceutical Inc. — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 69. 3% to $91. 50.

In this comparison, LAKE (1.

1% yield) pays a dividend. APT, SRPT, BMRN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alpha Pro Tech, Ltd.

(APT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), +209. 1% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (APT: +209. 1%, SRPT: +13. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (APT (Industrials) and SRPT (Healthcare) and BMRN (Healthcare) and LAKE (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: APT is a small-cap quality compounder stock; SRPT is a small-cap high-growth stock; BMRN is a mid-cap quality compounder stock; LAKE is a small-cap high-growth stock. LAKE pays a dividend while APT, SRPT, BMRN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.